BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34445227)

  • 21. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
    Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
    Remon J; Steuer CE; Ramalingam SS; Felip E
    Ann Oncol; 2018 Jan; 29(suppl_1):i20-i27. PubMed ID: 29462255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
    Yang Z; Yang J; Chen Y; Shao YW; Wang X
    Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.
    Buder A; Hochmair MJ; Filipits M
    Target Oncol; 2021 Jan; 16(1):77-84. PubMed ID: 33270169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
    Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
    Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
    Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y
    Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
    Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
    Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.
    Volta F; La Monica S; Leonetti A; Gnetti L; Bonelli M; Cavazzoni A; Fumarola C; Galetti M; Eltayeb K; Minari R; Petronini PG; Tiseo M; Alfieri R
    Target Oncol; 2023 Nov; 18(6):953-964. PubMed ID: 37855989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status.
    Takamizawa S; Okuma Y; Kato Y; Hakozaki T; Kitagawa S; Zenke Y
    Future Oncol; 2022 Jan; 18(3):291-300. PubMed ID: 34758637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Calvo E; Lee JS; Kim SW; Moreno V; deCastro Carpeno J; Weilert D; Laus G; Mann H; Vishwanathan K
    J Clin Pharmacol; 2019 Aug; 59(8):1099-1109. PubMed ID: 30875094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
    Shaikh M; Shinde Y; Pawara R; Noolvi M; Surana S; Ahmad I; Patel H
    J Med Chem; 2022 Jan; 65(2):1008-1046. PubMed ID: 34323489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
    Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
    J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
    Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
    Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Kita T; Hiraoka N; Ishizuka T; Kubota Y; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
    Oncologist; 2019 May; 24(5):593-e170. PubMed ID: 30651400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.